×
News Home

Is it Time to Dump Curis, Inc. (CRIS) Stock After it Is Up 3.37% in a Week?

Wednesday, April 14, 2021 11:00 AM | InvestorsObserver Analysts
Is it Time to Dump Curis, Inc. (CRIS) Stock After it Is Up 3.37% in a Week?

The market has been high on Curis, Inc. (CRIS) stock recently. CRIS gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,bullish
Curis, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRIS!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CRIS Stock Today?

Curis, Inc. (CRIS) stock is trading at $11.97 as of 10:58 AM on Wednesday, Apr 14, a gain of $0.60, or 5.28% from the previous closing price of $11.37. The stock has traded between $11.10 and $12.02 so far today. Volume today is light. So far 843,740 shares have traded compared to average volume of 2,068,063 shares.

To see InvestorsObserver's Sentiment Score for Curis, Inc. click here.

More About Curis, Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Click Here to get the full Stock Score Report on Curis, Inc. (CRIS) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App